A Phase 3, Single-Arm, Open Label Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug
Compared to Baseline in Patients with Inadequately Controlled Hypoglycemia Due to Tumor Associated Hyperinsulinism (Tumor HI)

Full Title

A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients with Inadequately Controlled Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI) (Advarra IRB)

Purpose

• To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. James Flory’s office at 646-608-2684.